We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
-31.86%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
–
AUM
$241M
AUM Growth
-$128M
Cap. Flow
-$8.57M
Cap. Flow %
-3.56%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$3.94M

Top Sells

Rank Stock Value
1
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$97.2M 40.37%
19,963,157
– –
AURA icon
2
Aura Biosciences
AURA
$725M
$43.1M 17.89%
3,039,892
– –
PCVX icon
3
Vaxcyte
PCVX
$7.81B
$41.1M 17.06%
1,887,478
– –
MRUS
4
DELISTED
Merus
MRUS
$36.2M 15.04%
1,600,000
– –
PHAT icon
5
Phathom Pharmaceuticals
PHAT
$708M
$20.7M 8.59%
2,450,679
+382,818
+19% +$3.94M
OBSV
6
DELISTED
ObsEva SA Ordinary Shares
OBSV
$2.53M 1.05%
1,570,000
– –
CMPI
7
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
– –
-1,501,716
Closed -$12.5M

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
FFS
Forge Financial Services Edmond, Oklahoma $987M AUM 14.12% 1-Year Est. Return
PCM
Polymer Capital Management New York $988M AUM 56.33% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Medicxi Ventures Management's Q2 2022 Portfolio in Review

As of Q2 2022, Medicxi Ventures Management held 7 positions worth $241M, down 35% from $369M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Medicxi Ventures Management withdrew a net $8.57M in Q2 2022, closing 1 position. Its most notable exit was Checkmate Pharmaceuticals, Inc. Common Stock, an estimated $12.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Medicxi Ventures Management added an estimated $3.94M to Phathom Pharmaceuticals.

  • Medicxi Ventures Management added most to Phathom Pharmaceuticals in Q2 2022, an estimated $3.94M increase.
  • Medicxi Ventures Management fully exited Checkmate Pharmaceuticals, Inc. Common Stock in Q2 2022, selling an estimated $12.5M.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $241M portfolio in Q2 2022.
  • Medicxi Ventures Management opened 0 new positions and closed 1 in Q2 2022.
  • Medicxi Ventures Management's portfolio value fell 35% quarter-over-quarter to $241M.

Based on Medicxi Ventures Management's 13F filing for Q2 2022, filed 3 Aug 2022.